Cyclin A as a Prognostic Indicator in Early Stage Breast Cancer
Author Information
Author(s): Michalides R, van Tinteren H, Balkenende A, Vermorken J B, Benraadt J, Huldij J, van Diest P
Primary Institution: Netherlands Cancer Institute
Hypothesis
Can cyclin A expression predict the outcome of tamoxifen treatment in early stage breast cancer?
Conclusion
Cyclin A is an independent predictor of recurrence in early stage breast cancer and indicates response to tamoxifen treatment.
Supporting Evidence
- Overexpression of cyclin A was found in 86 out of 201 OR-positive cases treated with tamoxifen.
- Univariate analysis showed that cyclin A expression was significantly associated with worse prognosis.
- Only cyclin A and Neu were independent markers of worse prognosis after adjusting for clinical factors.
Takeaway
This study found that cyclin A can help doctors understand how likely it is for breast cancer to come back after treatment with tamoxifen.
Methodology
The study used immunohistochemical staining to analyze cyclin A expression in tumor samples from 394 patients with early stage breast cancer.
Limitations
The study had a relatively short period of tamoxifen treatment, which may have influenced the results.
Participant Demographics
The study included post-menopausal women with early stage breast cancer.
Statistical Information
P-Value
0.0462
Confidence Interval
95% CI 0.55–0.80
Statistical Significance
p=0.0462
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website